TB and HIV-TB co-infection in Europe

Michel Kazatchkine
Graduate Institute for International Affairs and Development, Geneva
Special advisor to UNAIDS for Eastern Europe and central Asia
TB in the WHO European Region
2017 data

275 thousand people fell ill with TB (21,000 are children and 97,000 women)

34 thousand TB/HIV

77 thousand MDR-TB among notified TB

24 thousand people died from TB

Estimated TB incidence per 100,000 population
WHO European Region, 2017

Every 20 minutes, one person dies of TB
Heterogeneous distribution of TB burden in Europe, 2017

Incidence: 30/100,000 population
(< 2 – 144)
Decline is 4.7% per year

Mortality: 2.6/100,000 population
(0 - 10)

*18 high priority countries account for 87% of all TB cases:
Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Rep. Moldova, Romania, Russia, Tajikistan, Turkey, Turkmenistan, Ukraine, Uzbekistan
% of HIV co-infection among TB Patients *still rising*

New TB patients notified in the WHO European Region in 2017 was

1 in 8

**HIV positive**
\( \approx 160,000 \) new HIV diagnosis in the WHO European Region in 2017

Estimated new HIV infections and AIDS-related deaths (EECA)

Number of new HIV infections, eastern Europe and central Asia, 2000-2017

- Percentage change in new HIV infections since 2010 = +29%

Number of AIDS-related deaths, eastern Europe and central Asia, 2000-2017

- Percentage change in AIDS-related deaths since 2010 = +0.1%

Source: UNAIDS 2018 estimates.
Regional Progress towards 90-90-90 target
West, Centre, East (2017) (moving denominator)

Late diagnosis, linkage loss

Regional cascade: 82-66-84

Source: GAM, 2017
WHO European Region has fastest decline in TB incidence and TB mortality, halted MDR-TB notification and TB/HIV co-infection and.. still growing TB/HIV mortality
Treatment coverage of HIV-positive TB patients is low

• In 2017 91% of new TB patients in the WHO European region knew their HIV status.

• Only 67% of reported HIV-positive TB patients in 2017 started antiretroviral therapy.
TB/HIV co-infection diagnosis and treatment cascade in the WHO European Region

- People living with TB/HIV who know their status: 84%
- People living with TB/HIV started ART: 61%
- People living with TB/HIV - TB treatment outcomes available: 31%

TB treatment outcomes in TB/HIV co-infected people:
- Success: 63%
- Failed: 22%
- Lost to follow up: 8%
- Not evaluated: 3%
MDR-TB is one of key drivers of the TB epidemic in Europe

Every 5th new TB patient are found with MDR tuberculosis.

Every 2nd previously TB patient are found with MDR tuberculosis.

Source: WHO Europe / ECDC. Tuberculosis surveillance and monitoring in Europe 2017
Only about 62% of MDR-TB patients are detected (2017 data)

77 000 drug-resistant TB cases in WHO European Region

47 697 (62%) drug-resistant TB cases detected and enrolled on treatment

26 404 (57.2%) drug-resistant TB cases started treatment in 2015 with successful outcome

At least **10 countries** in the region have introduced **shorter MDR-TB regimens**.

**18 countries** started using bedaquiline and **18** had used delamanid by end of 2017.
TB Treatment outcomes
WHO European Region; 2017 Data

A slow but sustainable increase in successful treatment outcomes

<table>
<thead>
<tr>
<th>Category</th>
<th>Success</th>
<th>Died</th>
<th>Failed</th>
<th>Lost to follow-up</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>New&amp;Relapse</td>
<td>77.2</td>
<td>5.9</td>
<td>4.6</td>
<td>4.1</td>
<td>8.2</td>
</tr>
<tr>
<td>TB/HIV</td>
<td>62.9</td>
<td>24.9</td>
<td>7.5</td>
<td>5.0</td>
<td>5.0</td>
</tr>
<tr>
<td>RR/MDR</td>
<td>57.2</td>
<td>22.2</td>
<td>12.0</td>
<td>10.2</td>
<td>14.3</td>
</tr>
<tr>
<td>XDR-TB</td>
<td>35.1</td>
<td>10.6</td>
<td>25.7</td>
<td>8.7</td>
<td>19.9</td>
</tr>
</tbody>
</table>
HIV, HCV, TB/MDR-TB and drug use are major and closely interlinked challenges in EECA

- 40% of the > 3.5 million people who inject drugs in the region are infected with HIV, with large variations between countries.
- Two thirds of them are infected with HCV. Prevalence of HCV RNA among people who inject drugs estimated to be 45%.
- HCV co-infection rates among HIV-positive PWID are particularly high, often ranging between 70 and 90%.
- HIV-positive PWID have a two to six-fold higher risk of contracting TB. Almost all countries in the region are high burden countries for MDR TB.
- Prevalence of HIV and HCV much higher among prison inmates than in the general population.
Eastern Europe and Central Asia: incarceration

• High levels of incarceration, largely linked to criminalization of drug use.
• People who inject drugs, including those with HIV, hepatitis C and tuberculosis, are concentrated within prisons. There is little if no access to prevention programs in prisons and care may be sub-optimal.
• Mathematical modeling for Ukraine suggests that high levels of incarceration facilitate transmission with 28 - 55 % of new infections over the next 15 years predicted to be attributable to increased risk of transmission among currently or previously incarcerated people who inject drugs.

• Altice FL. Lancet 2016
Incarceration and Contribution to TB in Ukraine

PWID

- Data derived from nationally-representative prison\(^1,2\) and PWID community surveys\(^3\)

- Incarceration accounts for 6.2% of all incident TB cases (population-attributable fraction)

Community

- Among PWID, however, incarceration contributes to 75% of new TB cases in PWID with HIV

2. Azebi L et al, JIAS, 2014
Management of TB/HIV patient in Eastern Europe

ID Hospital

MTB+

Consultation of HIV specialist

TB Hospital

Discharged

AIDS Centre

CART

TB outpatient unit

TB treatment

Social support???
Integrated health care
A study from Ukraine

Quality Healthcare Indicators (QHI) based on service delivery setting:
HIV-Related Quality Healthcare Indicators

296 HIV+ IDUs
- Integrated co-located care
  - On site care for HIV, TB, OST
- Non-co-located care
  - OST only
- Harm reduction and outreach
  - but no OST

C Bachireddy et al., Drug Alcohol Depend. 2014
Figure 1: Overview of quantitative indicators 2015 versus target 2018

Source: TB-REP data
Note: This data was provided in January and is only partial.
Western Europe

• In high-income Western European countries, the incidence of TB is low, at pre-elimination levels (< 10 cases/ million).

• The epidemiology of TB is characterized by most cases occurring in people from high-incidence countries, often as a result of latent tuberculosis infection. Migrants from high tuberculosis burden countries have an increased risk of developing TB in the initial years after arrival in host country.

• Socio-economic conditions, delayed access to primary care services and not having been screened for TB prior to entry are associated with increased risk of post-entry active TB.
Western Europe

- Pre-entry tuberculosis screening, early primary care registration, post-entry screening for latent tuberculosis infection, are strongly and independently associated with a lower incidence of TB in new entrant migrants.
Progress towards the End-TB targets

SDG target: 90% reduction in number of TB deaths

- **Current pace:** -10.2%*
- **Target pace:** -14.2%

*5 years (2013-2017)

AP target: 35% reduction in number of TB deaths

- **Current pace:** -10.2%*
- **Target pace:** -8.2%
Progress towards the End-TB targets

SDG target: 80% reduction in incidence rate

- Current pace: -4.7%*
- Target pace: -10%

AP target: 25% reduction in incidence rate

- Current pace: -4.7%*
- Target pace: -5.6%
Acknowledgements

• Masoud Dara, Nicole Seguy, WHO Europe, Regional Office, Copenhagen